Cytokinetics gets up to $675m in expanded Astellas deal

Cytokinetics may earn up to $675m in upfront, milestone and other fees from Astellas after the companies expanded their skeletal muscle activator collaboration to advance CK-2127107 in spinal muscular atrophy (SMA) and other neuromuscular indications.